Endologix

Endologix

Financials

Estimates*

Edit
Revenues, earnings & profits over time
USD2016201720182019202020212022
Revenues-181m157m143m113m144m152m
% growth--(13 %)(9 %)(21 %)27 %6 %
EBITDA-(19.0m)(43.0m)(24.0m)(42.0m)(22.0m)-
% EBITDA margin-(10 %)(27 %)(17 %)(37 %)(15 %)-
Profit-(66.0m)(79.0m)(64.0m)(94.0m)(69.0m)-
% profit margin-(36 %)(50 %)(45 %)(83 %)(48 %)-
R&D budget34.1m------

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound
N/A

N/A

IPO
N/A

$9.0m

Post IPO Equity
N/A

$16.6m

Post IPO Equity

$15.0m

Post IPO Equity

$170m

Post IPO Debt
Total Funding-

Recent News about Endologix

Edit
More about Endologixinfo icon
Edit

Endologix is a medical device company specializing in innovative vascular therapies aimed at improving patient outcomes. The company focuses on developing groundbreaking solutions for the treatment of abdominal aortic aneurysms (AAA) and peripheral artery disease (PAD). Endologix serves healthcare professionals and patients by providing advanced medical devices that offer durable and personalized repair options. The company's flagship products include the AFX, Ovation, and ALTO systems, which are designed to preserve native bifurcation and ensure reliable, stable repairs. Endologix operates in the medical devices market and generates revenue through the sale of its specialized vascular therapy products. The business model revolves around continuous innovation and clinical excellence to meet the critical unmet needs in vascular care.

Keywords: vascular therapies, medical devices, AAA treatment, PAD solutions, healthcare professionals, patient outcomes, durable repair, personalized care, clinical excellence, innovation.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by Endologix

Edit
Nellix
ACQUISITION by Endologix Oct 2010
TriVascular, Inc
ACQUISITION by Endologix Oct 2015
PQ Bypass
ACQUISITION by Endologix Apr 2021